WHAT IS CLAIMED IS:

1. An agent that ~~reverses the hemodynamic effects of a natriuretic peptide receptor 1 (NPR1) agonist.~~

~~2. An agent that~~binds to and reverses a reduction in blood pressure associated with the administration of a natriuretic peptide receptor 1 (NPR1) agonist, wherein the agent is an immunoglobulin protein.

~~3. The agent of claim 1 or claim 2, wherein the agent is selected from the group consisting of an immunoglobulin protein, a vasopressor, an alpha-adrenoreceptor agonist, a steroid, an antidiuretic hormone, an angiogenesis inhibitor, and a small molecule agent that increases blood pressure.~~

~~4. The agent of any one of claims 1-3, wherein the agent is an immunoglobulin protein.~~

~~5. The agent of any one of claims 1-4, wherein the agent binds specifically to the NPR1 agonist.~~

~~6. The agent of any one of claims 1-5~~2. The agent of claim 1, wherein the NPR1 agonist is an antibody or antigen-binding fragment thereof that binds specifically to NPR1.

~~7.~~ 3. The agent of claim ~~6~~2, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) comprising SEQ ID NO: 48; and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) comprising SEQ ID NO: 52.

~~8.~~ 4. The agent of claim ~~6 or 7~~2, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) comprising SEQ ID NOs: 49, 50, and 51, respectively; and three light chain CDRs (LCDR1, LCDR2 and LCDR3) comprising SEQ ID NO: 53, 54, and 55, respectively.

~~9.~~ 5. The agent of claim ~~8~~4, wherein the antibody or antigen-binding fragment thereof comprises a HCVR of SEQ ID NO: 48 and a LCVR of SEQ ID NO: 52.

~~10. The agent of any one of claims~~ 6~~-9~~. The agent of claim 2, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody.

~~11.~~ 7. The agent of claim ~~10~~6, wherein the antibody is an IgG1 antibody.

~~12.~~ 8. The agent of claim ~~10~~6, wherein the antibody is an IgG4 antibody.

~~13.~~ 9. The agent of claim ~~10~~6, wherein the antibody comprises a heavy chain comprising SEQ ID NO: 56 and a light chain comprising SEQ ID NO: 57.

~~14.~~ 10. The agent of ~~any of claims~~claim 1~~-13~~, wherein the NPR1 agonist is R5381.

~~15. The agent of any one of claims 4-14, wherein the immunoglobulin protein comprises a monoclonal antibody or antigen-binding fragment thereof, a Fab fragment, F(ab)2 fragment, Fv fragment, Fd fragment, scFv, dAb, a bivalent monoclonal antibody, or a monovalent monoclonal antibody.~~

~~16.~~ 11. The agent of claim ~~15~~1, wherein the immunoglobulin protein comprises at least one immunoglobulin variable domain comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR~~).~~) , wherein the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 and 22; and the LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 30.

~~17.~~ 12. The agent of claim ~~15 or 16~~11, wherein the immunoglobulin protein comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) comprising amino acid sequences selected from SEQ ID NOs: 4, 6, 8, 12, 14 and 16; or SEQ ID NOs: 24, 26, 28, 32, 34, and 36.

~~18.~~ 13. The agent of claim ~~17~~12, wherein the HCVR comprises an amino acid sequence having at least 90%, optionally 95%, 98%, or 99% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2 and 22.

~~19.~~ 14. The agent of claim ~~17 or 18~~12, wherein the LCVR comprises an amino acid sequence having at least 90%, optionally 95%, 98%, or 99% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 10 and 30.

~~20.~~ 15. The agent of ~~any one of claims 17-19~~claim 12, wherein the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 and 22; and the LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 30.

~~21.~~ 16. The agent of ~~any one of claims 17-20~~claim 12, wherein the HCVR comprises an amino acid sequence of SEQ ID NO: 2 and the LCVR comprises an amino acid sequence of SEQ ID NO: 10.

~~22.~~ 17. The agent of ~~any one of claims 17-20~~claim 12, wherein the HCVR comprises an amino acid sequence of SEQ ID NO: 22 and the LCVR comprises an amino acid sequence of SEQ ID NO: 30.

~~23.~~ 18. The agent of ~~any one of claims 17-22~~claim 11, wherein the immunoglobulin protein comprises ~~a human monoclonal antibody comprising the at least~~ one immunoglobulin variable domain.

~~24.~~ 19. The agent of claim ~~23, wherein the human monoclonal antibody is of IgG1 or IgG4 isotype.~~

~~25. The agent of claim 23 or 24, wherein the human monoclonal antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:~~ 18 ~~and 38.~~

~~26. The agent of any one of claims 23-25, wherein the human monoclonal antibody comprises a heavy chain and a light chain, wherein the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 20 and 40.~~

~~27. The agent of any one of claims 4-15, wherein the immunoglobulin protein comprises one immunoglobulin variable domain.~~

~~28. The agent of claim 27, wherein the one immunoglobulin variable domain comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR), wherein HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 and 24; HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6 and 26; HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8 and 28; LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 12 and 32; LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 14 and 34; and LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16 and 36.~~

~~29. The agent of claim 28~~, wherein HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 comprise amino acid sequences selected from the group consisting of (i) SEQ ID NOs: 4, 6, 8, 12, 14 and 16; and (ii) SEQ ID NOs: 24, 26, 28, 32, 34, and 36.

~~30.~~ 20. The agent of claim ~~28 or 29~~19, wherein the HCVR comprises an amino acid sequence ~~having at least 90%, optionally 95%, 98% or 99% sequence identity to a sequence~~ selected from the group consisting of SEQ ID NOs: 2 and 22~~.~~

~~31. The agent of any one of claims 28-30, wherein~~ ; and the LCVR comprises an amino acid sequence ~~having at least 90%, optionally 95%, 98% or 99% sequence identity to a sequence~~ selected from the group consisting of SEQ ID NOs: 10 and 30.

~~32. The agent of any one of claims 28-31, wherein the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 and 22; and the LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 30.~~

~~33. The agent of any one of claims 28-32~~21. The agent of claim 19, wherein the HCVR comprises an amino acid sequence of SEQ ID NO: 2 and the LCVR comprises an amino acid sequence of SEQ ID NO: 10.

~~34.~~ 22. The agent of ~~any one of claims 28-32~~claim 19, wherein the HCVR comprises an amino acid sequence of SEQ ID NO: 22 and the LCVR comprises an amino acid sequence of SEQ ID NO: 30.

~~35.~~ 23. The agent of ~~any one of claims 26-34~~claim 20, wherein the one immunoglobulin variable domain is comprised within a Fab fragment.

~~36.~~ 24. The agent of ~~any one of claims 26-35~~claim 23, further comprising a multimerizing component.

~~37.~~ 25. The agent of claim ~~36~~24, wherein the multimerizing component comprises at least one Fc fragment.

~~38.~~ 26. The agent of claim ~~37~~25, wherein the at least one Fc fragment is of isotype IgG1, IgG4, or a variant thereof.

~~39.~~ 27. The agent of claim ~~38~~26, wherein the at least one Fc fragment is of IgG4 isotype.

~~40.~~ 28. The agent of claim ~~38~~26, wherein the at least one Fc fragment is of IgG1 isotype.

~~41.~~ 29. The agent of ~~any one of claims 37-40~~claim 25, comprising a first Fc fragment and a second Fc fragment, wherein the first Fc fragment or the second Fc fragment, but not both Fc fragments, comprises a modification in the CH3 domain that reduces binding of the

immunoglobulin protein to Protein A as compared to an immunoglobulin protein lacking the modification.

~~42.~~ 30. The agent of claim ~~41~~29, wherein the modification comprises a H315R substitution and a Y316F substitution (EU numbering) in a Fc fragment.

~~43.~~ 31. The agent of ~~any one of claims 37-42~~claim 25, wherein the multimerizing component comprises a first Fc fragment comprising the amino acid sequence of SEQ ID NO: 46 and a second Fc fragment comprising the amino acid sequence of SEQ ID NO: 58.

~~44.~~ 32. The agent of ~~any one of claims 16-22 or 26-34~~claim 18, wherein the immunoglobulin variable domain is comprised in a monovalent monoclonal antibody.

~~45.~~ 33. The agent of claim ~~44~~32, wherein the monovalent monoclonal antibody comprises a heavy chain comprising a heavy chain constant region and HCVR, and a light chain comprising a LCVR, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 42 and 44; and the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 20 and 40.

~~46.~~ 34. The agent of claim ~~45~~33, wherein the heavy chain constant region comprises a modification in the CH3 domain that reduces binding of the immunoglobulin protein to Protein A as compared to an immunoglobulin protein lacking the modification.

~~47.~~ 35. The agent of claim ~~46~~34, wherein the modification comprises a H315R substitution and a Y316F substitution (EU numbering) in the heavy chain constant region of IgG1 or IgG4 isotype.

~~48. The agent of any one of claims 45-47, wherein the heavy chain comprises an amino acid sequence of SEQ ID NO: 42 and the light chain comprises an amino acid sequence of SEQ ID NO: 20.~~

~~49. The agent of any one of claims 45-47, wherein the heavy chain comprises an amino acid sequence of SEQ ID NO: 44 and the light chain comprises an amino acid sequence of SEQ ID NO: 40.~~

~~50. The agent of any one of claims 44-49~~36. The agent of claim 33, wherein the immunoglobulin protein further comprises a Fc fragment.

~~51.~~ 37. The agent of claim ~~50~~36, wherein the Fc fragment is of IgG1 or IgG4 isotype.

~~52.~~ 38. The agent of claim ~~50 or 51~~36, wherein the Fc fragment comprises an amino acid sequence of SEQ ID NO: 46.

~~53.~~ 39. The agent of ~~any one of claims~~claim 1~~-52~~, wherein the agent is REGN9035 or REGN9037.

~~54.~~ 40. An isolated polynucleotide molecule comprising a polynucleotide sequence that encodes a heavy chain variable region (HCVR) of an immunoglobulin protein as set forth in ~~any one of claims 15-53~~claim 38.

~~55.~~ 41. An isolated polynucleotide molecule comprising a polynucleotide sequence that encodes a light chain variable region (LCVR) of an immunoglobulin protein as set forth in ~~any one of claims 15-53~~claim 38.

~~56.~~ 42. A vector comprising the polynucleotide molecule of claim ~~54 and/~~40 or the polynucleotide molecule of claim ~~55~~41.

~~57.~~ 43. A host cell expressing the vector of claim ~~56~~42.

~~58. The~~44. A host cell expressing the polynucleotide molecule of claim ~~57~~40 and the polynucleotide molecule of claim 41.

45. The host cell of claim 44, wherein the host cell is a CHO cell.

~~59.~~ 46. A method of producing an immunoglobulin protein, comprising growing the host cell of claim ~~57~~44 under conditions permitting production of the protein, and recovering the protein so produced.

~~60.~~ 47. The method of claim ~~59~~46, wherein the host cell is a CHO cell.

~~61. The agent of any one of claims 1-3, wherein the agent is a vasopressor.~~

~~62. The agent of claim 61, wherein the vasopressor is Midodrine.~~

~~63.~~ 48. A pharmaceutical composition comprising the agent of ~~any one of claims 1-53~~claim 1 and a pharmaceutically acceptable carrier or diluent.

~~64. A method of reversing the hemodynamic effects of a NPR1 agonist, the method comprising administering~~ 49. A pharmaceutical composition comprising a therapeutically effective amount of the agent of ~~any one of claims~~claim 1~~-53 to a subject~~ for use in ~~need thereof.~~

~~65. A method of~~ reversing the hemodynamic ~~changes associated with the administration~~effects of a NPR1 agonist, wherein the ~~method comprising administering a~~ pharmaceutical composition ~~comprising a therapeutically effective amount of the agent of any one of claims 1-53~~ is to be administered to a subject in need thereof.

~~66. The method of claim 64 or 65, wherein the~~50. The pharmaceutical composition ~~is~~for use of claim 49, wherein the composition is to be administered subcutaneously, intravenously, intradermally, intraperitoneally, or intramuscularly~~, or orally to the subject.~~

~~67. The method of any one of claims 64-66, wherein the NPR1 agonist is an antibody or antigen-binding fragment thereof that binds specifically~~ to ~~NPR1.~~ the subject.

~~68. The method of claim 67, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) comprising SEQ ID NO: 48; and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) comprising SEQ ID NO: 52.~~

~~69. The method of any one of claims 64-68, wherein the NPR1 agonist is R5381.~~

~~70. The method of any one of claims 64-69~~51. The pharmaceutical composition for use of claim 49, wherein the subject has a disease or disorder selected from the group consisting of hypertension, heart failure, and chronic kidney disease.

~~71. An antibody or antigen-binding fragment thereof that competes for binding with the agent of any one of claims 15-53.~~

~~72. An antibody or antigen-binding fragment thereof that binds to the same epitope as an agent of any one of claims 15-53.~~

~~73. An immunoglobulin protein comprising:~~

~~(a) a single immunoglobulin variable domain comprising a heavy chain variable region (HCVR), wherein the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 and 22, and a light chain variable region (LCVR), wherein the LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 30.~~

~~74. An immunoglobulin protein comprising:~~

~~(a) a single immunoglobulin variable domain comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR), wherein HCDR1-HCDR2-HCDR3 are selected from the group consisting of SEQ ID NOs: 4, 6, and 8, and 24, 26, and 28, and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within a light chain variable region (LCVR), wherein LCDR1-LCDR2-LCDR3 are selected from the group consisting of SEQ ID NOs: 12, 14, and 16, and 32, 34, and 36.~~

~~75. The immunoglobulin protein of claim 74, wherein:~~

~~(i) HCDR1 comprises the amino acid sequence of SEQ ID NO: 4, HCDR2 comprises the amino acid sequence of SEQ ID NO: 6, HCDR3 comprises the amino acid sequence of SEQ ID NO: 8, LCDR1 comprises the amino acid sequence of SEQ ID NO: 12, LCDR2 comprises the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 16; or~~

~~(ii) HCDR1 comprises the amino acid sequence of SEQ ID NO: 24, HCDR2 comprises the amino acid sequence of SEQ ID NO: 26, HCDR3 comprises the amino acid sequence of SEQ ID NO: 28, LCDR1 comprises the amino acid sequence of SEQ ID NO: 32, LCDR2 comprises the amino acid sequence of SEQ ID NO: 34, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 36.~~

~~76. The immunoglobulin protein of claim 74 or 75, wherein the HCVR comprises an amino acid sequence that has at least 90%, optionally 95%, 98%, or 99% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2 and 22.~~

~~77. The immunoglobulin protein of any one of claims 74-76, wherein the LCVR comprises an amino acid sequence that has at least 90%, optionally 95%, 98%, or 99% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 10 and 30.~~

~~78. The immunoglobulin protein of any one of claims 74-77, wherein the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 and 22; and wherein the LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 30.~~

~~79. The immunoglobulin protein of any one of claims 73-78, wherein:~~

~~(1) the HCVR comprises an amino acid sequence of SEQ ID NO: 2, and the LCVR comprises an amino acid sequence of SEQ ID NO: 10; or~~

~~(2) the HCVR comprises an amino acid sequence of SEQ ID NO: 22, and the LCVR comprises an amino acid sequence of SEQ ID NO: 30.~~

~~80. The immunoglobulin protein of any one of claims 73-79 further comprising a multimerizing component.~~

~~81. The immunoglobulin protein of claim 80, wherein the multimerizing component comprises at least one Fc fragment.~~

~~82. The immunoglobulin protein of claim 81, wherein the Fc fragment is of human IgG1 or IgG4 isotype.~~

~~83. The immunoglobulin protein of claim 81 or 82 comprising a first Fc fragment and a second Fc fragment, wherein the first Fc fragment or the second Fc fragment, but not both Fc fragments, comprises a modification in the CH3 domain that reduces binding of the immunoglobulin protein to Protein A as compared to an immunoglobulin protein lacking the modification.~~

~~84. The immunoglobulin protein of claim 83, wherein the modification comprises a H315R substitution and a Y316F substitution (EU numbering) in a Fc fragment.~~

~~85. The immunoglobulin protein of any one of claims 80-84, comprising a first Fc fragment that comprises the amino acid sequence of SEQ ID NO: 46 and a second Fc fragment that comprises the amino acid sequence of SEQ ID NO: 58.~~

~~86. The immunoglobulin protein of any one of claims 73-85 comprising a HCVR of SEQ ID NO: 2, a LCVR of SEQ ID NO: 10, and a multimerizing component, wherein the multimerizing~~

~~component comprises a first Fc fragment comprising the amino acid sequence of SEQ ID NO: 46 and a second Fc fragment comprising the amino acid sequence of SEQ ID NO: 58.~~

~~87. The immunoglobulin protein of any one of claims 73-85 comprising a HCVR of SEQ ID NO: 22, a LCVR of SEQ ID NO: 30, and a multimerizing component, wherein the multimerizing component comprises a first Fc fragment comprising the amino acid sequence of SEQ ID NO: 46 and a second Fc fragment comprising the amino acid sequence of SEQ ID NO: 58.~~

~~88. The immunoglobulin protein of any one of claims 73-79, wherein the immunoglobulin protein comprises a heavy chain comprising the HCVR and a heavy chain constant region and a light chain comprising the LCVR and a light chain constant region, wherein the heavy chain is of human IgG1 or IgG4 isotype.~~

~~89. The immunoglobulin protein of claim 88, wherein the heavy chain constant region comprises a modification in the CH3 domain that reduces binding of the immunoglobulin protein to Protein A as compared to an immunoglobulin protein lacking the modification.~~

~~90. The immunoglobulin protein of claim 89, wherein the modification comprises a H315R substitution and a Y316F substitution (EU numbering) in the heavy chain constant region of IgG1 or IgG4 isotype.~~

~~91. The immunoglobulin protein of any one of claims 88-90, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 42 and 44.~~

~~92. The immunoglobulin protein of any one of claims 88-91, wherein the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 20 and 40.~~

~~93. The immunoglobulin protein of any one of claims 88-92, wherein:~~

~~(i) the heavy chain comprises an amino acid sequence of SEQ ID NO: 42, and the light chain comprises an amino acid sequence of SEQ ID NO: 20; or~~

~~(ii) the heavy chain comprises an amino acid sequence of SEQ ID NO: 44, and the light chain comprises an amino acid sequence of SEQ ID NO: 40.~~

~~94. The immunoglobulin protein of any one of claims 88-93 further comprising a multimerizing component.~~

~~95. The immunoglobulin protein of claim 94, wherein the multimerizing component comprises a Fc fragment.~~

~~96. The immunoglobulin protein of claim 96, wherein the Fc fragment is of human IgG1 or IgG4 isotype.~~

~~97. The immunoglobulin protein of claim 95 or 96, wherein the Fc fragment comprises an amino acid sequence of SEQ ID NO: 46.~~

~~98. The immunoglobulin protein of any one of claims 88-97 comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 42, a light chain comprising the amino acid sequence of SEQ ID NO: 20, and a Fc fragment comprising the amino acid sequence of SEQ ID NO: 46.~~

~~99. The immunoglobulin protein of any one of claims 88-97 comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 44, a light chain comprising the amino acid sequence of SEQ ID NO: 40, and a Fc fragment comprising the amino acid sequence of SEQ ID NO: 46.~~

~~100. The immunoglobulin protein of any one of claims 73-99, wherein the immunoglobulin protein binds specifically to a NPR1 agonist.~~

~~101. The immunoglobulin protein of claim 100, wherein the NPR1 agonist is an antibody or antigen-binding fragment thereof that binds specifically to NPR1.~~

~~102. The immunoglobulin protein of claim 101, wherein the antibody or antigen-binding fragment thereof comprises a HCVR comprising an amino acid sequence of SEQ ID NO: 48 and a LCVR comprising an amino acid sequence of SEQ ID NO: 52.~~

~~103. The immunoglobulin protein of any one of claims 100-102, wherein the NPR1 agonist is R5381.~~

~~104. The immunoglobulin protein of any one of claims 73-103, wherein the immunoglobulin protein is REGN9035 or REGN9037.~~

~~105. An isolated polynucleotide molecule comprising a polynucleotide sequence that encodes a HCVR of an immunoglobulin protein as set forth in any one of claims 73-104.~~

~~106. An isolated polynucleotide molecule comprising a polynucleotide sequence that encodes a LCVR of an immunoglobulin protein as set forth in any one of claims 73-104.~~

~~107. A vector comprising the polynucleotide molecule of claim 105 and/or the polynucleotide molecule of claim 106.~~

~~108. A host cell expressing the vector of claim 107.~~

~~109. The host cell of claim 108, wherein the host cell is a CHO cell.~~

~~110. A method of producing an immunoglobulin protein, comprising growing the host cell of claim 108 under conditions permitting production of the protein, and recovering the protein so produced.~~

~~111. The method of claim 110, wherein the host cell is a CHO cell.~~

~~112. A pharmaceutical composition comprising the immunoglobulin protein of any one of claims 73-104 and a pharmaceutically acceptable carrier or diluent.~~

~~113. A method of reversing the hemodynamic effects of a NPR1 agonist, the method comprising administering a pharmaceutical composition comprising a therapeutically effective amount of the immunoglobulin protein of any one of claims 73-104 to a subject in need thereof.~~

~~114. A method of reversing hemodynamic changes associated with the administration of a NPR1 agonist, the method comprising administering a pharmaceutical composition comprising a therapeutically effective amount of the immunoglobulin protein of any one of claims 73-104 to a subject in need thereof.~~

~~115. The method of claim 113 or 114, wherein the composition is administered subcutaneously, intravenously, intradermally, intraperitoneally, intramuscularly, or orally to the subject.~~

~~116. The method of any one of claims 113-115, wherein the NPR1 agonist is an antibody or antigen-binding fragment thereof that binds specifically to NPR1.~~

~~117. The method of claim 116, wherein the antibody or antigen-binding fragment thereof comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 48 and a LCVR comprising the amino acid sequence of SEQ ID NO: 52.~~

~~118. The method of any one of claims 113-117, wherein the NPR1 agonist is R5381.~~

~~119. The method of any one of claims 113-118, wherein the subject has a disease or disorder selected from the group consisting of hypertension, heart failure, and chronic kidney disease.~~

~~120. An antibody or antigen-binding fragment thereof that competes for binding with an immunoglobulin protein of any one of claims 73-104.~~

~~121. An antibody or antigen-binding fragment thereof that binds to the same epitope as an immunoglobulin protein of any one of claims 73-104.~~

~~122. A composition comprising: (i) the immunoglobulin protein of any one of claims 73-104; and (ii) an NPR1 agonist.~~

~~123. The composition of claim 122, wherein the NPR1 agonist is an antibody or antigen-binding fragment thereof that binds specifically to NPR1.~~

~~124. The composition of claim 123, wherein the antibody or antigen-binding fragment thereof comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 48 and a LCVR comprising the amino acid sequence of SEQ ID NO: 52.~~

~~125. The composition of any one of claims 122-124, wherein the NPR1 agonist is R5381.~~

~~126. The composition of any one of claims 122-125 for use in a method for effective regulation of blood pressure in a subject in need thereof.~~

~~127. The composition of claim 126, wherein the subject has a NPR1-associated disease or disorder.~~

~~128. The composition of claim 127, wherein the disease or disorder is selected from the group consisting of hypertension, heart failure, and chronic kidney disease.~~